March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
April 2023 in “JMIR Research Protocols” In this study, researchers are constructing a comprehensive data set from 997 adult participants in Japan to develop a statistical model that explores the relationships among various health parameters, aiming to enable personalized and preventive health care interventions based on empirical data.
19 citations
,
January 2018 in “Scientific Reports” This study provided the first proteome dataset for alopecia areata, revealing novel pathways in the disease mechanisms that may lead to new therapeutic targets.
This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.
This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.